Attached files
file | filename |
---|---|
10-K - FORM 10-K - ALSERES PHARMACEUTICALS INC /DE | b84090e10vk.htm |
EX-21 - EX-21 - ALSERES PHARMACEUTICALS INC /DE | b84090exv21.htm |
EX-31.2 - EX-31.2 - ALSERES PHARMACEUTICALS INC /DE | b84090exv31w2.htm |
EX-32.2 - EX-32.2 - ALSERES PHARMACEUTICALS INC /DE | b84090exv32w2.htm |
EX-32.1 - EX-32.1 - ALSERES PHARMACEUTICALS INC /DE | b84090exv32w1.htm |
EX-31.1 - EX-31.1 - ALSERES PHARMACEUTICALS INC /DE | b84090exv31w1.htm |
EX-10.61 - EX-10.61 - ALSERES PHARMACEUTICALS INC /DE | b84090exv10w61.htm |
EX-10.54 - EX-10.54 - ALSERES PHARMACEUTICALS INC /DE | b84090exv10w54.htm |
EX-10.60 - EX-10.60 - ALSERES PHARMACEUTICALS INC /DE | b84090exv10w60.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statements on Forms S-3 (Nos.
333-146171, 333-113015, 333-112123, 333-88726, 333-44298, 333-40408, 333-89159, 333-75175 and
333-74775), and Forms S-8 (Nos. 333-158375, 333-149108, 333-144516, 333-130454, 333-67384,
333-67386, 333-80065, 333-80067 and 333-80069) of Alseres Pharmaceuticals, Inc. and Subsidiaries of
our report dated March 31, 2011, relating to our audit of the consolidated financial statements,
which appears in the Annual Report on Form 10-K of Alseres Pharmaceuticals, Inc. and Subsidiaries
for the year ended December 31, 2010. Our report dated March 31, 2011, relating to the consolidated
financial statements includes an emphasis paragraph relating to an uncertainty as to the Companys
ability to continue as a going concern.
/s/ McGladrey & Pullen, LLP
Boston, MA
March 31, 2011
Boston, MA
March 31, 2011